Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smart pens and sensors could transform diabetes care after hospital stay

NCT ID NCT07061301

Recruiting now Disease control Sponsor: Instituto de Investigacion Sanitaria La Fe Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether giving people with type 2 diabetes a continuous glucose monitor and a smart insulin pen cap (Insulclock) at hospital discharge helps them stick to their insulin schedule and control blood sugar better than standard finger-prick checks. About 80 adults aged 18-70 who are starting insulin in the hospital will be followed for 12 weeks after discharge. The goal is to see if technology reduces missed doses and improves time in target blood sugar range.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CGM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

congenital primary megaureter type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CGM CONTINUOUS GLUCOSE MONITORING SMART INSULIN PEN CAP TRANSITION TO DISCHARGE TYPE 2 DIABETES MELLITUS (T2DM)

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Hospital La Fe, Valencia

    RECRUITING

    Valencia, Valencia, 46026, Spain

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.